A pro-inflammatory cytokine family (primarily IL-1α and IL-1β) that serves as a primary endogenous pyrogen, orchestrates acute phase responses, and functions as a critical alarm signal communicating tissue damage, infectious disease, and metabolic disturbance to both immune system and nervous system. IL-1 acts at the intersection of immunity and metabolism, resetting physiological set points during inflammation and driving sickness behaviour via brain-immune axis signaling.
Think of IL-1 as the fire alarm system in a large building complex. When smoke (DAMPs) is detected, the alarm doesn't just ring—it requires two separate confirmation signals before the full emergency protocol activates. First, the building's security system (NF-κB) needs to arm the alarm (priming), then the actual smoke detector (NLRP3 inflammasome) must confirm the threat and cut the wire that releases the alarm bell (caspase-1 cleaving pro-IL-1β into active IL-1β).
Once the alarm sounds, it doesn't just alert the fire department—it fundamentally changes how the entire building operates. The thermostat gets reset to a higher temperature (fever via PGE2), energy is redirected to emergency systems (HPA axis activation), normal daily activities shut down (fatigue, sickness behaviour), and the building goes into lockdown mode (acute phase response). The alarm also has an automatic shut-off mechanism (IL-1 receptor antagonist, IL-1Ra) that's released simultaneously to prevent the alarm from running indefinitely—like a fire suppression system that activates after the initial alert.
Critically, this alarm doesn't work in isolation. It calls in backup alarms (TNF-α, Interleukin-6) that amplify the signal, creating a cascade of emergency responses throughout the entire complex. The alarm reaches the brain not by crossing the main barrier (blood-brain barrier) but through special communication points (Circumventricular organs) where messages can pass through, like emergency intercoms positioned at key locations.
IL-1 production and signaling follows a tightly regulated two-signal pathway:
IL-1β Processing Cascade:
- Priming Signal (Signal 1): PAMPs or DAMPs bind TLR4 or other pattern recognition receptors → activate NF-κB → transcription of pro-IL-1β (inactive precursor) and NLRP3 inflammasome components
- Activation Signal (Signal 2): Cellular stress signals (K⁺ efflux, mitochondrial ROS, extracellular ATP) → NLRP3 inflammasome oligomerization → recruitment of ASC adaptor protein and pro-caspase-1 → autocatalytic activation of caspase-1
- Maturation: Active caspase-1 cleaves pro-IL-1β (31 kDa) → mature IL-1β (17 kDa) → secreted via non-classical pathways (gasdermin D pores, exosomes, microvesicles)
Receptor Signaling:
- IL-1β binds IL-1 receptor type I (IL-1R1) → recruits IL-1 receptor accessory protein (IL-1RAcP) → forms high-affinity receptor complex
- Intracellular TIR domain recruits MyD88 adaptor → activates IRAK1/4 kinases → TRAF6 ubiquitination → TAK1 activation
- TAK1 bifurcates to:
- NF-κB pathway: IKK complex → IκB phosphorylation and degradation → NF-κB (p65/p50) nuclear translocation → transcription of inflammatory genes (IL-6, TNF-α, COX-2, iNOS)
- MAPK pathway: JNK, ERK, p38 activation → AP-1 transcription factor → amplification of inflammatory response
Brain Signaling:
Negative Regulation:
- IL-1 receptor antagonist (IL-1Ra) competes for IL-1R1 binding without activating downstream signaling (decoy mechanism)
- IL-1Ra:IL-1β ratio normally 10-100:1; shifts to <10:1 during chronic inflammation
- Soluble IL-1R2 (decoy receptor) binds IL-1β without signaling
- SOCS3 inhibits IL-1R signaling via negative feedback
graph TD
A[PAMPs/DAMPs] -->|TLR4| B["NF-κB Activation"]
B --> C["Pro-IL-1β Transcription"]
D[Cellular Stress] -->|"K+ efflux, ROS, ATP"| E[NLRP3 Inflammasome]
C --> F["Pro-IL-1β Protein"]
E --> G[Caspase-1 Activation]
F --> G
G --> H["Mature IL-1β"]
H --> I[IL-1 Receptor]
I --> J[MyD88/IRAK/TRAF6]
J --> K[TAK1]
K --> L["NF-κB Pathway"]
K --> M[MAPK Pathway]
L --> N[Inflammatory Genes]
M --> N
H --> O[Circumventricular Organs]
O --> P["COX-2 → PGE2"]
P --> Q[Hypothalamic EP3]
Q --> R["Fever + HPA Activation"]
H --> S[Vagus Nerve IL-1R]
S --> T["NTS → Brain"]
U[IL-1Ra] -.->|Inhibits| I
IL-1 dysregulation is central to multiple chronic disease states and represents a key intervention target in cPNI practice.
Chronic Low-Grade Inflammation:
Autoinflammatory Syndromes:
- Cryopyrin-associated periodic syndromes (CAPS): gain-of-function NLRP3 mutations → constitutive IL-1β production
- Anakinra (recombinant IL-1Ra) is therapeutic: blocks IL-1R → suppresses fever, rash, and systemic inflammation within hours
- Demonstrates the critical role of IL-1Ra:IL-1β ratio in maintaining immunological homeostasis
Neuroinflammation and Depression:
Pain Syndromes:
Intervention Implications:
- Reduce NLRP3 priming: anti-inflammatory diet (↓ AGEs, saturated fat), optimize vitamin D (inhibits NF-κB), omega-3 fatty acids (compete with arachidonic acid)
- Inhibit NLRP3 activation: ketogenic diet (β-hydroxybutyrate directly inhibits NLRP3), cold exposure (↓ mitochondrial ROS), adequate sleep (↓ cellular stress signals)
- Enhance IL-1Ra: exercise (↑ IL-1Ra production from skeletal muscle), SCFAs from fiber fermentation (↑ IL-1Ra:IL-1β ratio)
- Targeted supplementation: curcumin (NF-κB inhibitor), resveratrol (SIRT1 activation → ↓ NLRP3), NAC (↓ oxidative stress)
- Clinical thresholds: IL-1β >10 pg/mL indicates significant inflammatory activation; IL-1Ra <200 pg/mL suggests inadequate counter-regulatory response
Connection to Selfish Systems:
- IL-1 exemplifies the selfish immune system: prioritizes immune defense over metabolic health (insulin resistance protects glucose for immune cells)
- Creates competition with selfish brain for energy resources during infection
- Chronic activation represents failure of resolution mechanisms → persistent redirection of resources to immunity
- IL-1β requires two distinct signals for production: NF-κB-mediated transcription (Signal 1) and NLRP3 inflammasome-mediated cleavage (Signal 2)
- Normal serum IL-1β: <1-2 pg/mL; >5 pg/mL indicates significant inflammatory activation; >10 pg/mL seen in acute infection or autoinflammatory disease
- IL-1Ra:IL-1β ratio normally 10-100:1 in healthy individuals; ratio <10:1 associated with chronic inflammatory diseases
- IL-1β has a half-life of only 6-9 minutes in circulation but creates sustained effects via transcriptional cascades
- PGE2-mediated fever typically increases body temperature by 1-4°C via hypothalamic thermostat reset at median preoptic nucleus
- IL-1β synergizes with TNF-α: together they induce 10-100× more inflammatory mediators than either alone
- First cytokine discovered to cause fever (1940s) and first cytokine antagonist approved for clinical use (anakinra, 2001)
- Single nucleotide polymorphisms in IL-1β gene (rs16944) associated with 2-3× variation in cytokine production capacity
- Exercise-induced IL-1Ra increases 40-100 fold in circulation, providing anti-inflammatory protection for 24-48 hours post-exercise
- IL-1α (constitutively present) vs IL-1β (inducible): IL-1α released from necrotic cells as immediate alarm; IL-1β requires inflammasome activation for controlled release
- NLRP3 inflammasome — required for proteolytic processing of pro-IL-1β into bioactive mature form via caspase-1 cleavage
- NF-κB — master transcription factor that drives pro-IL-1β gene expression during priming phase and is activated downstream of IL-1R signaling
- TNF-α — synergistic pro-inflammatory cytokine that amplifies IL-1 effects and shares downstream NF-κB signaling pathways
- Interleukin-6 — secondary cytokine induced by IL-1 that mediates hepatic acute phase response and systemic metabolic changes
- PGE2 — lipid mediator synthesized via IL-1-induced COX-2 that mediates fever and central nervous system effects
- HPA axis — neuroendocrine stress system activated by IL-1 via vagal afferents and circumventricular organ signaling
- sickness behaviour — adaptive behavioral program (fatigue, anhedonia, social withdrawal) triggered by IL-1 effects on brain
- fever — IL-1 is primary endogenous pyrogen acting via PGE2 to reset hypothalamic thermostat
- Circumventricular organs — specialized brain regions lacking blood-brain barrier where IL-1 signals enter CNS
- acute phase proteins — hepatic proteins (C-reactive protein, fibrinogen, serum amyloid A) induced by IL-6 downstream of IL-1
- insulin resistance — IL-1β directly impairs insulin signaling via IRS-1 serine phosphorylation in metabolic tissues
- DAMPs — endogenous danger signals (HMGB1, ATP, uric acid) that activate NLRP3 inflammasome and IL-1β production
- metaflammation — chronic low-grade inflammation in metabolic disease driven by persistent IL-1 signaling
- central sensitization — IL-1 from activated glia enhances spinal cord excitability and pain amplification
- IDO — enzyme induced by IL-1 in brain that depletes tryptophan and generates neurotoxic kynurenine metabolites
- cortisol resistance — IL-1-induced impairment of glucocorticoid receptor function creating failed anti-inflammatory feedback
- depression — IL-1-mediated neuroinflammation contributes to treatment-resistant depression via kynurenine pathway activation
- Type 2 Diabetes — chronic IL-1β elevation in islets causes beta-cell dysfunction and contributes to disease progression
- atherosclerosis — IL-1β in arterial plaques drives endothelial dysfunction and promotes plaque rupture
- Rheumatoid arthritis — synovial IL-1β mediates cartilage destruction via matrix metalloproteinase induction and osteoclast activation
- exercise — acute exercise transiently increases IL-1β but massively upregulates IL-1Ra, creating net anti-inflammatory effect
- ketogenic diet — β-hydroxybutyrate directly inhibits NLRP3 inflammasome assembly, reducing IL-1β production
- sleep deprivation — increases cellular stress signals that prime NLRP3 and elevate baseline IL-1β levels
- gut permeability — intestinal barrier dysfunction allows LPS translocation that primes systemic IL-1β production
- microbiome — commensal bacteria produce metabolites (butyrate) that suppress IL-1β while pathogens activate inflammasome